Logo

Xbrane Resubmit the BLA for Ranibizumab Biosimilar to Treat Serious Eye Disease

Share this
Xbrane Resubmit the BLA for Ranibizumab Biosimilar to Treat Serious Eye Disease

Xbrane Resubmit the BLA for Ranibizumab Biosimilar to Treat Serious Eye Disease

Shots:

  • The US FDA offers a general advice letter with comments & recommendations for the resubmission of the BLA for the biosimilar candidate to Lucentis, based on the preliminary review. In 2022, the company is anticipated to resubmit the BLA
  • Xbrane withdrew the BLA for its biosimilar candidate to Lucentis at the end of May while the FDA stated that additional information was necessary to make the decision to accept the BLA and initiate a full review within 60 days post resubmission
  • The company will advance its biosimilar candidate towards approval in the US to offer patients with serious eye disease an affordable therapy option

Ref: XBRANE | Image: XBRANE

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions